Novartis data show once-daily Ultibro® Breezhaler® is superior in COPD

Novartis presented new data that demonstrated once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and improving lung function compared to twice-daily Seretide®Accuhaler®* (salmeterol/fluticasone (SFC)), in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Industry News Respiratory copd exacerbation indacaterol/glycopyrronium bromide Latest News lung function Source Type: news